Conducted by SoLongevity Research in collaboration with Sacco Hospital in Milan, the study will assess in more than 150 patients the efficacy of the nutraceutical on the redox state and on the symptoms of the disease, in particular on tiredness, brain fog and sleep quality.
After GluRes, SoLongevity’s first patent, the GluReNAD nutraceutical formulation is also covered by a patent: by mimicking the effects of caloric restriction, it regulates metabolism and also helps reduce the sense of hunger thanks to the energy boost provided by the synergy of glutathione, resveratrol and NAD
Longevity genes can be activated with a specific mix of nutrients. This is what prompted SoLongevity research to develop a special formulation: a combination of amino acids, polydatin and NAC which, in a controlled clinical trial, proved effective in rebalancing oxidative stress and reducing inflammatory parameters.
